Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
Atopic Dermatitis
Interventions
DRUG

Placebo

Pharmaceutical form: Tablet Route of administration: Oral

DRUG

Rilzabrutinib

Pharmaceutical form: Tablet Route of administration: Oral

Trial Locations (31)

29420

National Allergy and Asthma Research, LLC. Site Number : 8400007, North Charleston

30599

Investigational Site Number : 2030002, Pilsen

33173

Florida International Research Center Site Number : 8400002, Miami

39157

Integrative Skin Care of MS/SKYCRNG Site Number : 8400011, Ridgeland

40217

Skin Sciences, PLLC Site Number : 8400005, Louisville

40241

DS Research of Kentucky, LLC Site Number : 8400004, Louisville

48455

Investigational Site Number : 2760001, Bad Bentheim

53002

Investigational Site Number : 2030003, Pardubice

78759

Orion Clinical Research Site Number : 8400003, Austin

79903

E.P.I.M.R.D dba Western Sky Research, Inc. Site Number : 8400009, El Paso

80907

Asthma and Allergy Associates, PC Site Number : 8400008, Colorado Springs

88045

Investigational Site Number : 2760002, Friedrichshafen

89600

Investigational Site Number : 6160008, Chojnice

91325

Antelope Valley Clinical Trials Site Number : 8400001, Northridge

7580206

Investigational Site Number : 1520004, Santiago

7640881

Investigational Site Number : 1520001, Santiago

8420383

Investigational Site Number : 1520002, Santiago

T4P 1K4

Investigational Site Number : 1240008, Red Deer

P3E 5M4

Investigational Site Number : 1240013, Greater Sudbury

N6A2C2

Investigational Site Number : 1240001, London

L3P 1X3

Investigational Site Number : 1240002, Markham

M2N 3A6

Investigational Site Number : 1240011, Toronto

M3H 5Y8

Investigational Site Number : 1240007, Toronto

G1V 4T3

Investigational Site Number : 1240004, Québec

779 00

Investigational Site Number : 2030004, Olomouc

160 00

Investigational Site Number : 2030001, Prague

3584 CX

Investigational Site Number : 5280001, Utrecht

90-436

Investigational Site Number : 6160001, Lodz

80-546

Investigational Site Number : 6160005, Gdansk

93-530

Investigational Site Number : 6160002, Lodz

00-215

Investigational Site Number : 6160004, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY